IKT - Inhibikase Therapeutics GAAP EPS of -$0.18 revenue of $0.01M November, 15 2022 09:02 AM Inhibikase Therapeutics Inc. Inhibikase Therapeutics press release ( NASDAQ: IKT ): Q3 GAAP EPS of -$0.18. Revenue of $0.007M (vs. $0.33M Y/Y). Cash, cash equivalents and marketable securities were $26.5M as of September 30, 2022. For further details see: Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $0.01M